Listing 3 - Actual negotiations

Indication:

In combination with carboplatin and pemetrexed for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal-growth factor receptor (EGFR) Exon 19 deletions or Exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with osimertinib.

Indication:

For the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations.

Indication:

In combination with bortezomib, lenalidomide, and dexamethasone, followed by maintenance treatment in combination with lenalidomide, for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.

Indication:

In combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with activating epidermal-growth factor receptor (EGFR) exon 20 insertion mutations.

Indication:

Multiple Sclerosis, Relapsing-Remitting

Indication:

Adult patients undergoing minor gynecological, ambulatory, or emergency procedures

Indication:

Acromegaly in Adults

Indication:

Indicated to delay the onset of stage 3 type 1 diabetes (T1D) in adult and pediatric patients 8 years of age and older with stage 2 T1D

Indication:

Crohn's disease

Indication:

Ulcerative Colitis